You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for troglitazone


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for troglitazone

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial T2573_SIGMA ⤷  Start Trial
Calbiochem ⤷  Start Trial 648469 ⤷  Start Trial
NovoSeek ⤷  Start Trial 5591 ⤷  Start Trial
ISpharm ⤷  Start Trial I14-1977 ⤷  Start Trial
MolPort ⤷  Start Trial MolPort-003-666-725 ⤷  Start Trial
ABI Chem ⤷  Start Trial AC1L1KOT ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Troglitazone

Last updated: February 20, 2026

Troglitazone, a thiazolidinedione class drug previously used for type 2 diabetes, was withdrawn from the market due to safety concerns. Its bulk API sourcing involves identifying reliable manufacturers with the capacity to produce pharmaceutical-grade compounds adhering to regulatory standards.

Manufacturers and Suppliers of Troglitazone API

Certified API Suppliers

Few suppliers currently produce troglitazone API, primarily for research and legacy manufacturing purposes. Sourcing from these suppliers requires validation of Good Manufacturing Practice (GMP) compliance.

Supplier Name Location Certification Production Capacity Notes
TCI Chemicals Japan GMP, ISO 9001 Limited capacity Supplies for research use only
Toronto Research Chemicals Canada Non-GMP, Research Small scale Focuses on research quantities
LGM Pharma United States GMP Limited Offers custom synthesis for limited batches
Target Molecule Corp China GMP, ISO 9001 Modest capacity Provides bulk API for global markets

Market Landscape

  • Research-Grade Vendors: Offer small quantities, suitable for preclinical trials or laboratory research.
  • GMP-Certified Manufacturers: Enable commercial production but are scarce for troglitazone due to market withdrawal.
  • Custom Synthesis Firms: Can produce batches on demand; often operate under confidentiality agreements.

Sourcing Challenges

  • Regulatory Restrictions: Use of troglitazone API is restricted for clinical development or research, limiting manufacturer's willingness to produce.
  • Market Discontinuation: Market withdrawal minimized production, leading to limited supply availability.
  • Quality Assurance: Due to safety concerns, strict verification of purity and adherence to GMP standards is mandatory.

Regulatory and Compliance Considerations

  • GMP Compliance: Sourcing from suppliers with GMP certification reduces regulatory risks.
  • Exportation Restrictions: Certain jurisdictions impose export controls on APIs linked to discontinued or withdrawn drugs.
  • Documentation: Certificates of Analysis (CoA) and batch records are essential for validation of API quality.

Alternative Sources and Routes

  • Repurposing or Resynthesis: Some companies may resynthesize troglitazone for research, but such processes can be complex and costly.
  • Ingredient Repositories: Academic institutions and research consortia occasionally maintain stocks, usually for non-commercial use.

Market Outlook

  • Limited Commercial Demand: Decline in clinical use reduces procurement activity.
  • Research Applications: Still used in specialized laboratory research, maintaining a niche supply market.
  • Potential for Toxicology Studies: Limited API available for toxicity evaluations or legacy drug research.

Summary

Sourcing troglitazone API entails navigating a fragmented supply chain dominated by small research vendors and a handful of GMP-certified manufacturers. Market discontinuation and safety issues limit commercial production, making procurement primarily suitable for research or limited pharmacological investigations.


Key Takeaways

  • Troglitazone API is mainly available for research and legacy purposes.
  • Few GMP-certified suppliers operate due to market withdrawal.
  • Quality verification remains critical when sourcing from non-commercial vendors.
  • Regulatory restrictions influence supply dynamics, especially for export and use.
  • Alternative synthesis routes are limited and costly.

FAQs

1. Why was troglitazone withdrawn from the market?
It was withdrawn because of safety concerns, primarily due to hepatotoxicity linked to its use.

2. Are there GMP-certified vendors selling troglitazone API today?
Few vendors provide GMP-grade troglitazone API, mostly for research purposes; large-scale commercial production has ceased.

3. Can I source troglitazone API for clinical trials?
Only if the supplier complies with GMP standards and regulatory approval, which is challenging given the drug's market withdrawal status.

4. How can I verify the quality of troglitazone API?
Request Certificates of Analysis, review batch documentation, and conduct independent testing if necessary.

5. Are there substitutes for troglitazone in research?
Other thiazolidinediones like pioglitazone and rosiglitazone may serve as alternatives depending on the research application.


References

[1] U.S. Food and Drug Administration. (2000). Final rule: Withdrawal of troglitazone (Rezulin). https://www.fda.gov/

[2] European Medicines Agency. (2000). Scientific discussion on troglitazone. https://www.ema.europa.eu/

[3] Toronto Research Chemicals. (2023). Troglitazone high-purity API supplier info. https://trcfrom.com/

[4] LGM Pharma. (2023). Custom synthesis of APIs. https://lgmpharma.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.